Drug Discovery

How Will Aurigene's New Biologics Facility Impact Drug Development?
Research & Development How Will Aurigene's New Biologics Facility Impact Drug Development?

In the bustling bio-cluster of Genome Valley, Hyderabad, sits a new beacon of innovation: Aurigene Pharmaceutical Services' sprawling 70,000-square-foot biologics facility. This strategic extension, an affiliate of Dr. Reddy’s Laboratories, heralds a new era for biopharmaceutical development and

Is the AGC Biologics-BioConnection Alliance Transforming Biopharma?
Research & Development Is the AGC Biologics-BioConnection Alliance Transforming Biopharma?

In an industry where time-to-market is critical, a strategic collaboration between AGC Biologics, a global leader in biopharmaceutical development, and BioConnection, an aseptic filling expert, may be the key to unlocking faster pathways from laboratory to patient. As biotechnology firms grapple

BIO Weighs Impact of Biosecurity Bill on Drug Developers
Biotech & Bioprocessing BIO Weighs Impact of Biosecurity Bill on Drug Developers

The biotechnology sector could be on the brink of a substantial change as legislative gears turn with the possibility of the BIOSECURE Act being widened to encompass drug developers. This pivot towards inclusive scrutiny, primarily targeting relationships with Chinese biopharma entities, sparks a

How Is Lab Automation Transforming Drug Development?
Research & Development How Is Lab Automation Transforming Drug Development?

The rapid pace and intricate processes of modern drug development call for efficiency, precision, and scalability—goals that are increasingly being met through the adoption of laboratory automation technologies. From target identification to quality control, these systems enhance biopharma research

Can AI Revolutionize Cancer Drug Development?
Research & Development Can AI Revolutionize Cancer Drug Development?

In a pivotal step toward enhancing cancer treatment, Oregon Therapeutics has joined forces with Lantern Pharma to escalate the development of a pivotal cancer drug, XCE853. This collaborative venture showcases AI's potential to transform medical innovations and potentially bring groundbreaking

How Will AI Propel XCE853's Cancer Drug Development?
Research & Development How Will AI Propel XCE853's Cancer Drug Development?

In the evolving landscape of pharmaceuticals, the strategic partnership between Lantern Pharma and Oregon Therapeutics marks a significant milestone in the use of artificial intelligence (AI) for drug development. This collaboration centers on the advanced cancer drug candidate XCE853, an inhibitor

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later